Published in FASEB J on February 01, 2001
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol (2002) 4.31
Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J (2010) 2.36
Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J Virol (2004) 2.06
IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J Virol (2008) 1.89
Bunyamwera virus nonstructural protein NSs counteracts interferon regulatory factor 3-mediated induction of early cell death. J Virol (2003) 1.67
The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I- and TBK-1-directed interferon responses. J Virol (2006) 1.66
The interferon stimulated gene 54 promotes apoptosis. J Biol Chem (2010) 1.58
The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev (2007) 1.48
Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J Virol (2005) 1.38
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol (2006) 1.37
Phosphorylation of IRF-3 on Ser 339 generates a hyperactive form of IRF-3 through regulation of dimerization and CBP association. J Virol (2008) 1.19
A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A (2008) 1.19
Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis. Nat Struct Mol Biol (2010) 1.19
Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol (2005) 1.17
The DNA damage response induces IFN. J Immunol (2011) 1.13
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol (2005) 1.13
Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur J Immunol (2009) 1.12
The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology (2012) 1.02
Cell type-dependent proapoptotic role of Bcl2L12 revealed by a mutation concomitant with the disruption of the juxtaposed Irf3 gene. Proc Natl Acad Sci U S A (2009) 0.97
A death-promoting role for ISG54/IFIT2. J Interferon Cytokine Res (2013) 0.96
Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA. J Virol (2002) 0.91
Interferon regulatory transcription factor 3 protects mice from uterine horn pathology during Chlamydia muridarum genital infection. Infect Immun (2011) 0.82
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Recycling of the general transcription factors during RNA polymerase II transcription. Genes Dev (1995) 3.88
Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol Cell Biol (1998) 3.70
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology (1983) 2.69
Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Mol Cell Biol (2000) 2.24
Nuclear export signal located within theDNA-binding domain of the STAT1transcription factor. EMBO J (2000) 2.24
The amino acid sequence of murine p53 determined from a c-DNA clone. Virology (1984) 2.15
Double-stranded RNA activates novel factors that bind to the interferon-stimulated response element. Mol Cell Biol (1993) 2.03
Definitive percutaneous treatment of Lutembacher's syndrome. Catheter Cardiovasc Interv (1999) 2.00
Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4. Science (1993) 2.00
IRF-3-dependent and augmented target genes during viral infection. Genes Immun (2007) 1.94
Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol (1982) 1.82
Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci U S A (1991) 1.54
Characterization of specific DNA-binding factors activated by double-stranded RNA as positive regulators of interferon alpha/beta-stimulated genes. J Biol Chem (1995) 1.48
Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci U S A (2001) 1.46
The epithelial cell response to rotavirus infection. J Immunol (1999) 1.44
Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene (2006) 1.40
Tyrosine phosphorylation is required for activation of an alpha interferon-stimulated transcription factor. Proc Natl Acad Sci U S A (1992) 1.22
Specific interaction of the SV40 T antigen-cellular p53 protein complex with SV40 DNA. Virology (1982) 1.22
Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3. J Biol Chem (1997) 1.20
Transmembrane signaling by interferon alpha involves diacylglycerol production and activation of the epsilon isoform of protein kinase C in Daudi cells. Proc Natl Acad Sci U S A (1991) 1.19
Extensive proliferation of mature connective-tissue type mast cells in vitro. Nature (1986) 1.10
Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. Proc Natl Acad Sci U S A (1994) 1.09
Long-term follow-up assessment of vascularized rib pedicle graft for tuberculosis kyphosis. J Pediatr Orthop (2001) 1.05
Cooperation of the transcriptional coactivators CBP and p300 with Stat6. J Interferon Cytokine Res (1999) 1.04
Interleukin-4-induced STAT6 recognizes and activates a target site in the promoter of the interleukin-4 receptor gene. J Biol Chem (1996) 1.04
Signal transduction and activation of gene transcription by interferons. Gene Expr (1995) 1.00
Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes. Proc Natl Acad Sci U S A (1995) 0.98
Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res (2001) 0.98
Cloning and nucleotide sequence of the gene encoding arginine deiminase of Mycoplasma arginini. Infect Immun (1990) 0.97
Hemodialysis in treatment of acute chloral hydrate poisoning. South Med J (1977) 0.96
Characterization of the interleukin-4 nuclear activated factor/STAT and its activation independent of the insulin receptor substrate proteins. J Biol Chem (1995) 0.96
Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem (1997) 0.95
Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ. Lymphokine Res (1988) 0.93
Anterior spinal decompression in HIV-positive patients with tuberculosis. A prospective study. J Bone Joint Surg Br (2001) 0.90
Biodegradation of cyanides, cyanates and thiocyanates to ammonia and carbon dioxide by immobilized cells of Pseudomonas putida. J Ind Microbiol Biotechnol (1998) 0.87
Tuberculosis of the cervicodorsal junction. J Pediatr Orthop (2001) 0.87
Interferon signal transduction. Biotherapy (1996) 0.85
Single-cell origin of human mixed hemopoietic colonies expressing various combinations of cell lineages. Blood (1985) 0.85
Trehazolin, a new trehalase inhibitor. J Antibiot (Tokyo) (1991) 0.84
Aspergillus spondylitis in immunocompetent patients. Int Orthop (2001) 0.83
Receptor to nucleus signaling via tyrosine phosphorylation of the p91 transcription factor. Trends Endocrinol Metab (2008) 0.82
Interferon alpha (IFN alpha) signaling in cells expressing the variant form of the type I IFN receptor. J Biol Chem (1994) 0.81
Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant. Int J Oncol (1998) 0.81
Prolonged constriction of sciatic nerve affecting oxidative stressors & antioxidant enzymes in rat. Indian J Med Res (2009) 0.81
Monoclonal antibodies as probes for monitoring the denaturation process of bovine beta-lactoglobulin. Biochim Biophys Acta (1989) 0.80
Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. Int J Oncol (2001) 0.80
Spinal tuberculosis in HIV positive and negative patients: immunological response and clinical outcome. Int Orthop (2000) 0.79
Tyrosinase gene transcription and its control by melanogenic inhibitors. J Invest Dermatol (1993) 0.78
Reduction of glycogen in eggs of the silkworm, Bombyx mori, by use of a trehalase inhibitor, trehazolin, and diapause induction in glycogen-reduced eggs. J Insect Physiol (1998) 0.78
Neuropeptide Y gene polymorphisms are not associated with obesity in a South Indian population. Eur J Clin Nutr (2010) 0.77
Heparin modulates the single channel kinetics of reconstituted AMPA receptors from rat brain. Synapse (1999) 0.76
IL-12 promotes the accessory cell function of epidermal Langerhans cells. J Dermatol Sci (1998) 0.75
[Multipotential hemopoietic progenitors in acute leukemia in childhood]. Nihon Ketsueki Gakkai Zasshi (1987) 0.75
[An improved culture method without human plasma for megakaryocyte colony formation: megakaryocyte colony forming cells (CFU-M) in human umbilical cord blood]. Nihon Ketsueki Gakkai Zasshi (1985) 0.75
[Drug-induced pancytopenia and systemic lupus erythematosus. Immune suppression of hemopoietic progenitor cells in the presence of the patient's peripheral blood cells, acute serum and the drug]. Rinsho Ketsueki (1984) 0.75
Establishment of new interferon-gamma-resistant mutant cells with dominant phenotypes. J Interferon Cytokine Res (1995) 0.75
[A case of CML blast crisis with numerous megakaryocyte and basophil colony formations]. Rinsho Ketsueki (1985) 0.75
[Secondary colony forming capabilities of multipotential hemopoietic progenitors in human bone marrow]. Nihon Ketsueki Gakkai Zasshi (1987) 0.75
Processing glucosidase inhibition by 1-azafagomine. Biosci Biotechnol Biochem (2000) 0.75
[Heterogeneity of human mixed hemopoietic colonies derived from marrow cells]. Nihon Ketsueki Gakkai Zasshi (1986) 0.75
Two kinds of cytochrome c from the heart muscle of bonito, possibly due to age. J Biochem (1968) 0.75
[Successful treatment of severe aplastic anemia in an infant with cyclic thrombocytopenia by high-dose intravenous gammaglobulin]. Rinsho Ketsueki (1988) 0.75
Right internal jugular vein approach as an alternative in balloon pulmonary valvuloplasty. Catheter Cardiovasc Interv (1999) 0.75
Bovine seminalplasmin [corrected] is a DNA unwinding protein. FEBS Lett (1988) 0.75
[Remodeling of the gingivae after the forced eruption]. Nihon Rinsho Shishubyo Danwakai Kaishi (1990) 0.75
The crystal structure of L-valine hydrochloride. Acta Crystallogr (1967) 0.75
[A case of severe aplastic anemia with successful allogeneic bone marrow transplantation--subsequent analysis of hemopoiesis]. Rinsho Ketsueki (1984) 0.75
Studies on riboflavin kinase and FAD pyrophosphorylase. J Vitaminol (Kyoto) (1968) 0.75
Molecular anatomy of the transcription complex of Escherichia coli during initiation. Indian J Biochem Biophys (1992) 0.75
Hemopoietic progenitors before and after bone marrow transplantation. Nihon Ketsueki Gakkai Zasshi (1986) 0.75
Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines. Cancer (1998) 0.75
Coronary stenting without pre-dilatation: an observational study. Indian Heart J (2000) 0.75
Low dose metoprolol in acute myocardial infarction. Indian Heart J (1989) 0.75
High expression of glycosphingolipids involved in procoagulant activity of cancer cells. Oncol Rep (1999) 0.75
Le(y) glycolipid acts as a co-factor for tumor procoagulant activity. Int J Cancer (1997) 0.75